Back to search
FDAFDA · Food and drugs·Recall number D-0881-2017

Estradiol (17-B-Estradiol; Estra-1,3,5(10)-triene-3, 17B-diol; Oestradiol) Plant Base, Micronized, U.S.P active pharmaceutical ingredient, packaged in 1g, 5g, 25g, 6 x 25g, and 100g containers, Rx only, Spectrum Chemical Mfg. Corp, Gardena, CA 90248, New Brunswick, NJ 08901, Product code E1435.

Published June 14, 2017 · Recall initiated: April 13, 2017

Summary

FDA records drug Class II recall D-0881-2017, published June 14, 2017 and initiated April 13, 2017. Recalling firm: Spectrum Laboratory Products, Inc.; Status: Terminated; Reported quantity: 48 containers; Lot: Lot #: 2FH0257, Exp 09/30/2017; 2GA0254, Exp 03/24/2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: these repackaged and redistributed products are being recalled due to a recall notice from the active pharmaceutical ingredient manufacturer for deviations from current Good Manufacturing Practices that were found during a recent FDA inspection.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Spectrum Laboratory Products, Inc.
Distributor
Nationwide in the USA
Lot
Lot #: 2FH0257, Exp 09/30/2017; 2GA0254, Exp 03/24/2018
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Estradiol (17-B-Estradiol; Estra-1,3,5(10)-triene-3, 17B-diol; Oestradiol) Plant Base, Micronized, U.S.P active pharmaceutical ingredient, packaged in 1g, 5g, 25g, 6 x 25g, and 100g containers, Rx only, Spectrum Chemical Mfg. Corp, Gardena, CA 90248, New Brunswick, NJ 08901, Product code E1435. recalled?

Yes. FDA published recall D-0881-2017 on June 14, 2017. Reported hazard: CGMP Deviations: these repackaged and redistributed products are being recalled due to a recall notice from the active pharmaceutical ingredient manufacturer for deviations from current Good Manufacturing Practices that were found during a recent FDA inspection.

What should I do if I have this product?

Voluntary: Firm initiated · Letter